Oncothermia Shows Promise in Advanced pancreatic Cancer Treatment, Study finds
Table of Contents
A novel cancer therapy, oncothermia, is demonstrating significant potential in improving outcomes for patients with advanced pancreatic cancer, notably those who have developed resistance to traditional treatments. New research highlights the technique’s ability to enhance the effectiveness of chemotherapy, radiotherapy, and immunotherapy, offering a beacon of hope on World Pancreatic Cancer Day.
Boosting Treatment Effectiveness with targeted Heat
The Medical Institute of Advanced Oncology (INMOA) has been at the forefront of research into oncological hyperthermia, a localized treatment that utilizes radiofrequency waves to selectively increase the temperature of tumor tissue. This targeted heating weakens cancer cells, making them more susceptible to conventional therapies.
“The goal is to overcome the inherent challenges in treating pancreatic cancer,” a senior official stated. “The tumor’s poor vascularization and low oxygen levels frequently enough hinder drug delivery and radiation effectiveness.”
Addressing the Challenges of Pancreatic Cancer
Pancreatic cancer is notoriously arduous to treat due to its aggressive nature and the often-late stage at which it is diagnosed.The disease frequently presents with compromised blood vessels and limited oxygenation within the tumor itself. These conditions severely impede the delivery of chemotherapy and diminish the efficacy of radiotherapy, which relies on oxygen to prevent cancer cell repair.
Oncothermia addresses these issues by actively improving blood flow and oxygen levels within the tumor microenvironment. This, in turn, facilitates better drug penetration and maximizes the impact of radiation treatment.
How Electromodulated Hyperthermia Works
Electromodulated hyperthermia – also known as ‘Oncothermia’ or ‘mEHT’ – exhibits a unique selectivity for malignant cells, minimizing damage to healthy tissue and avoiding an increase in the toxicity associated with standard cancer treatments. The therapy can be employed as a standalone treatment in certain cases, or, more commonly, in conjunction with chemotherapy or radiotherapy to amplify their effects.
Clinical Trial Demonstrates Improved Survival Rates
Recent clinical research provides compelling evidence supporting the benefits of oncothermia. A study involving 158 patients with advanced and metastatic pancreatic cancer (stages III and IV) revealed a notable increase in both overall survival and progression-free survival in patients receiving oncothermia (mEHT), compared to patients receiving chemotherapy alone.
These findings, according to a company release, “confirm the therapeutic value of oncothermia as a highly potential adjuvant in the treatment of advanced pancreatic tumors.” The study suggests that integrating oncothermia into existing treatment protocols could substantially improve patient outcomes and quality of life.
Expanded News Report:
Why: Researchers are investigating oncothermia as a way to overcome the challenges of treating advanced pancreatic cancer, which often resists conventional therapies due to poor blood flow and oxygen levels within the tumor.
who: The Medical institute of Advanced Oncology (INMOA) led the research. The study involved 158 patients with stages III and IV pancreatic cancer. A senior official from INMOA provided a statement.
What: A clinical trial demonstrated that adding oncothermia (mEHT) to standard chemotherapy significantly improved overall survival and progression-free survival rates in patients with advanced pancreatic cancer. Oncothermia uses radiofrequency waves to heat tumor tissue, making cancer cells more susceptible to treatment
